SeekInClarity: Breakthrough Blood Test Revolutionizes Cancer Treatment Monitoring

In a significant advancement for cancer treatment monitoring, a new prospective study published in the journal *BMC Cancer* on July 2, 2025, reveals that the SeekInClarity blood-based multi-omics test can effectively assess and predict therapeutic outcomes in lymphoma patients across various subtypes. This innovative approach could transform the standard methods used by clinicians to track treatment responses, enhancing patient care and outcomes.

The SeekInClarity test integrates genomic, epigenetic, and proteomic signals derived from blood samples to generate a molecular tumor burden (MTB) score. This non-invasive alternative to conventional imaging techniques offers a promising new tool in the management of lymphoma. According to Dr. Mao Mao, the corresponding author and Founder & CEO of SeekIn Inc., “Our findings underscore the clinical value of integrating multi-omics liquid biopsy approaches like SeekInClarity into routine lymphoma management.”

The study enrolled 116 newly diagnosed lymphoma patients from two major cancer centers in China, where blood samples were collected before and after two treatment cycles. The results indicated a strong correlation between higher MTB scores and advanced tumor stages. Specifically, patients who maintained a positive MTB status following two cycles of treatment exhibited significantly worse progression-free and overall survival rates.

Traditional monitoring methods, such as positron emission tomography-computed tomography (PET-CT) and computed tomography (CT) imaging, while valuable, can be costly and limited in sensitivity. The SeekInClarity assay presents a cost-effective solution that enhances risk stratification for patients, allowing for earlier interventions for those unlikely to respond to standard therapies.

The study's findings reveal that molecular responses measured by SeekInClarity, along with interim PET/CT results, were the only independent predictors of treatment outcomes, surpassing established clinical biomarkers such as beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH). This capability is particularly crucial for identifying high-risk patients earlier in their treatment journey, which can guide more personalized treatment decisions.

Furthermore, the research indicates that even among patients with a favorable interim PET/CT response, SeekInClarity was able to identify a subgroup of molecular non-responders who were at considerably higher risk of disease progression, particularly in aggressive lymphoma subtypes. This insight could significantly impact clinical practices by providing clearer guidance on treatment adaptations.

The collaborative study, involving leading hospitals in China, was designed to validate the SeekInClarity test against interim PET/CT imaging and standard clinical biomarkers. The robust predictive power of the molecular response framework was particularly evident in aggressive B-cell and NK/T-cell lymphomas.

Looking ahead, the research paves the way for broader adoption of blood-based multi-omics monitoring not only in lymphoma but potentially across other cancer types. As SeekIn Inc. continues to refine its innovative testing methodologies, the healthcare community may witness a paradigm shift towards more effective cancer management and improved patient outcomes.

SeekInClarity, which received the CE-IVD Mark in May 2022, aims to provide comprehensive monitoring of treatment responses across various cancers and treatment regimens, including chemotherapy, targeted therapy, and immunotherapy. The multi-omics test leverages shallow whole-genome sequencing of cell-free DNA to map the cancer genome, integrating analysis of copy number variations, fragment size, and multiple protein biomarkers. This cutting-edge technology positions SeekIn Inc. at the forefront of cancer diagnostics, aiming to revolutionize early detection and treatment monitoring in oncology. For further details about SeekIn's advancements, visit www.seekincancer.com.